As per the company, Nerivio, priced at Rs 14,000-16,000, utilizes remote electrical neuromodulation to stimulate nerve endings and activate conditioned pain modulation. This initiates a natural pain-relieving process in the brainstem, resulting in pain inhibition that targets the source of migraine pain in the head. The device, which comes with 18 sessions lasting 45 minutes each, should be used within 60 minutes of the onset of a headache for acute migraine treatment or every alternate day for migraine prevention. Once the 18 sessions are complete, the device should be replaced with a new one.
Controlling the intensity levels of the device is a mobile app that accompanies it. The app also includes an interactive migraine diary to log symptoms, track responses, and provide insightful analytics. Additionally, it features a Guided Imagery, Education, and Relaxation (GIER) protocol that, when used in conjunction with the device, can significantly enhance response rates.
M V Ramana, CEO of Branded Markets (India & Emerging Markets) at Dr Reddy’s, stated that the launch of this device marks the company’s entry into the realm of digital therapeutics. This development follows Dr Reddy’s exclusive agreement with Theranica Bio-electronics, an Israeli digital therapeutics company specializing in advanced neuromodulation devices for migraine and pain management.